Coronary disease & ACS

Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: final 7-year results of the COMPARE-ABSORB trial

EuroInterventionPublished investigator-initiated, prospective randomised study

Primary result · Target lesion failure (TLF): composite of cardiac death, TVMI, or CI-TLRResult — go to the resultHazard ratio 1.14 95% CI 0.76–1.77

Authors' conclusion

After complete resorption, no benefit was observed with BVS compared with EES at 7-year follow-up, despite the use of a dedicated implantation protocol for BVS. In fact, after 3 years, more target lesion revascularisations occurred with BVS than with EES.

Study context

Population
Patients at high risk of restenosisenrolment stopped at 80% of the intended 2,100 patients · bioresorbable vascular scaffolds (BVS) 848 · everolimus-eluting stents (EES) 822
Participants
1,670 patients
Comparison
BVS vs EES
  • BVSn = 848
  • EESn = 822reference
Primary endpoint
Target lesion failure (TLF): composite of cardiac death, TVMI, or CI-TLR
Follow-up
7-year subsequent to a 3-year landmark analysis
Methodological details3-year landmark analysis
  • 3-year landmark analysis

Primary result

As reported in the abstract

Target lesion failure (TLF): composite of cardiac death, TVMI, or CI-TLR

Hazard ratio

1.14

95% CI 0.76–1.77

P = 0.53

By group

BVS vs EES
HR 1.14 (95% CI 0.76–1.77); P = 0.53

Further findings

OutcomeBVSEESHR (95% CI)P value
CI-TLR · 7-year follow-up · significantly higher in the BVS arm4.4%2.2%1.97 (1.08–3.60)P = 0.023

Cardiac death, target vessel myocardial infarction (TVMI), and device thrombosis · 7-year follow-up

Rates did not differ between both groups

Early stop of enrolment

Enrolment stopped because of high thrombosis and TVMI rates in the BVS arm
1,670 patients (80% of the intended 2,100 patients)

Original publication

Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: final 7-year results of the COMPARE-ABSORB trial. EuroIntervention. Published 16 February 2026. doi:10.4244/eij-d-25-00778

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.